Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
12 Results Found
AHA Letter to HRSA Regarding a New Concerning Development with the 340B Program
AHA letter to the Health Resources and Services Administration about a new concerning development with the 340B Program.
AHA Comments on CMS Proposed GLOBE Model
While the AHA broadly supports the Administration’s objectives as described in the proposed rule, we believe the GLOBE Model as proposed lacks critical operational details that, if not properly clarified, could create additional burden for hospitals and health systems.
AHA Comments on HRSA’s RFI Re: 340B Rebate Model Pilot Program – HHS Docket No. HRSA-2026-03042
The American Hospital Association's initial comment on the Health Resources and Services Administration’s (HRSA) request for information regarding a 340B Rebate Model Pilot Program.
AHA Urges HRSA to Stop Eli Lilly’s New Policy on 340B Hospitals From Going into Effect
The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all dispensations of all Lilly drugs, regardless of setting.
AHA Letter to HRSA Re: The 340B Rebate Model Pilot Program
AHA comments on the Health Resources and Services Administration’s (HRSA) information collection request (ICR) regarding the expected costs of its 340B Rebate Model Pilot Program.
AHA Details Legislative Priorities for Congressional Leaders
Hospitals and health systems are experiencing significant financial pressures that challenge their ability to provide 24/7 care for the patients and communities they serve. As Congress begins to focus on its end-of-the-year work, America’s hospitals and health systems respectfully request that you consider the following priorities.
AHA Letter to FTC and DOJ Re: Anticompetitive Activity by Drug Companies with Respect to 340B “Rebate Models”
AHA letter to the Federal Trade Commission and Department of Justice regarding anticompetitive activity by drug companies with respect to 340B “rebate models.”
AHA Comments to HRSA on Proposed 340B Rebate Model Pilot Program
AHA comments on the Health Resources and Services Administration’s notice of the 340B Rebate Model Pilot Program.
AHA, Health Associations Comment on HRSA Notice of a 340B Rebate Model Pilot Program
AHA, health associations initial comment on the Health Resources and Services Administration’s (HRSA) notice of a 340B Rebate Model Pilot Program.
AHA Urges HHS to Reject the Effort by Several Large Drug Companies to Undermine the 340B Drug Pricing Program
AHA urges Secretary U.S. Department of Health and Human Services to reject the effort by several large drug companies to undermine the 340B Drug Pricing Program by imposing a “rebate model,”